微信公众号

官网二维码

中国癌症防治杂志 ›› 2024, Vol. 16 ›› Issue (5): 562-565.doi: 10.3969/j.issn.1674-5671.2024.05.08

• CAR-T细胞治疗专栏 • 上一篇    下一篇

BCMA CAR-T细胞治疗复发/难治性浆母细胞淋巴瘤:个案研究与临床启示

  

  1. 首都医科大学附属北京同仁医院血液科
  • 出版日期:2024-10-25 发布日期:2024-11-06
  • 通讯作者: 王亮 E-mail:wangliangtrhos@126.com
  • 基金资助:
    国家重点研发计划项目(2022YFF1502000);国家自然科学基金项目(82170181;82370188);北京市自然科学基金项目(7222027);北京市医师科学家培养计划(BJPSTP-2024-01)

BCMA CAR-T cell therapy for relapsed/refractory plasmablastic lymphoma: case report and clinical implication

  • Online:2024-10-25 Published:2024-11-06
  • Supported by:
    国家重点研发计划项目(2022YFF1502000);国家自然科学基金项目(82170181;82370188);北京市自然科学基金项目(7222027);北京市医师科学家培养计划(BJPSTP-2024-01)

摘要:  浆母细胞淋巴瘤(plasmablastic lymphoma,PBL)是一种罕见的侵袭性大B细胞淋巴瘤亚型,预后较差且目前缺乏标准治疗方案。常用的治疗策略包括化疗、蛋白酶体抑制剂、免疫调节剂、CD30和CD38单克隆抗体以及自体造血干细胞移植等均未获得理想的治疗结果。嵌合抗原受体T(chimeric antigen receptor T,CAR⁃T)细胞疗法已为弥漫性大B细胞淋巴瘤和多发性骨髓瘤的管理带来了变革,这也为PBL患者带来了希望。然而,目前尚缺乏CAR⁃T细胞在PBL治疗中应用的经验及数据支持。本文报告1例老年PBL患者在接受B细胞成熟抗原CAR⁃T细胞治疗后获得完全缓解的经验。

关键词: 浆母细胞淋巴瘤, 嵌合抗原受体T细胞, B细胞成熟抗原, 复发, 难治

Abstract: Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of large B⁃cell lymphoma, with a poor prognosis without standardized treatment protocols. Traditional therapeutic strategies, such as chemotherapy, proteasome inhibitors, immunomodulatory agents, CD30 and CD38 monoclonal antibodies, and autologous hematopoietic stem cell transplantation, have yielded suboptimal outcomes. Chimeric antigen receptor T (CAR⁃T) cell therapy has revolutionized the management of diffuse large B⁃cell lymphoma and multiple myeloma, offering hope for patients with PBL. However, clinical experience and data evidence supporting the application of CAR⁃T cell in PBL treatment remain scant. This paper reports a case of an elderly patient with PBL who achieved a complete response following B⁃cell maturation antigen CAR⁃T cell therapy. 

Key words: Plasmablastic lymphoma, Chimeric antigen receptor T-cell, B?cell maturation antigen, Relapsed, Refractory

中图分类号: 

  • R733.4